Zydus Lifesciences announced a major licensing and commercialization agreement with Zhuhai Beihai Biotech Co. to market Beizray (Albumin Solubilized Docetaxel Injection) in the United States. The deal, signed through Zydus Lifesciences Global FZE, marks a significant step in expanding the company’s oncology portfolio in the high-demand US market.
Roles & Commercial Terms
Under the agreement, Zhuhai Beihai Biotech will handle manufacturing and supply, while Zydus will oversee commercialization of Beizray in the US. The financial terms include upfront payments, milestone-based sales incentives, and a share of net profits earned in the US market.
Beizray’s Therapeutic Use
Beizray is an advanced formulation of Docetaxel designed for the treatment of multiple cancers, including:
- Breast Cancer
- Non-Small Cell Lung Cancer
- Prostate Cancer
- Gastric Adenocarcinoma
- Head and Neck Cancer
Leadership Comments
Punit Patel, President & CEO of Zydus Pharmaceuticals (USA) Inc., emphasized that the deal aligns with the company’s focus on high-unmet-need therapies, reinforcing its commitment to expanding access to critical cancer treatments.
Meanwhile, Qun Sun, Founder & Chairman of Zhuhai Beihai Biotech, stated that Beizray represents a first-of-its-kind improved Docetaxel formulation, offering significant clinical benefits and a much-needed treatment alternative for cancer patients in the US.
Also read: ₹99,858 Cr Health Budget to Boost Cancer Care & Treatment Access
Implications for Zydus and the US Market
This partnership positions Zydus as a key player in the oncology segment, strengthening its presence in the US pharmaceutical landscape. The agreement aligns with Zydus’ broader strategy of bringing innovative and cost-effective therapies to global markets, especially in high-demand oncology treatments.
